Federica Ruffini

发表

Platelet-derived growth factor C and calpain-3 are modulators of human melanoma cell invasiveness.

L. Tentori, P. Lacal, D. Arcelli, 2013, Oncology reports.

Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib

P. Marchetti, P. Lacal, L. Levati, 2017, Oncotarget.

miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A

A. Carè, N. Felli, P. Lacal, 2019, Journal of Experimental & Clinical Cancer Research.

Glucocorticoid-Induced Tumor Necrosis Factor Receptor Family-Related Ligand Triggering Upregulates Vascular Cell Adhesion Molecule-1 and Intercellular Adhesion Molecule-1 and Promotes Leukocyte Adhesion

C. Riccardi, P. Lacal, G. Migliorati, 2013, The Journal of Pharmacology and Experimental Therapeutics.

Microsoft Word-26264595-file00.docx

C. Riccardi, P. Lacal, G. Migliorati, 2013 .

An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells.

P. Lacal, E. Pagani, F. Ruffini, 2005, International journal of oncology.

Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis.

C. Leonetti, M. Scarsella, Zhao-Qi Wang, 2007, European journal of cancer.

Inhibition of endothelial cell migration and angiogenesis by a vascular endothelial growth factor receptor-1 derived peptide.

A. Tramontano, L. Tentori, P. Lacal, 2008, European journal of cancer.

Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor.

A. Ciucci, M. Pesce, P. Lacal, 2006, The American journal of pathology.

A proangiogenic peptide derived from vascular endothelial growth factor receptor-1 acts through alpha5beta1 integrin.

A. Tramontano, P. Lacal, L. Morbidelli, 2008, Blood.

factor receptor-1 acts through A proangiogenic peptide derived from vascular endothelial growth

P. Lacal, L. Morbidelli, M. Ziche, 2013 .

A proangiogenic peptide derived from vascular endothelial growth factor receptor-1 acts through α5β1 integrin

A. Tramontano, P. Lacal, L. Morbidelli, 2008 .

The Anti–Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody D16F7 Inhibits Glioma Growth and Angiogenesis In Vivo

L. Tentori, P. Lacal, M. Atzori, 2018, The Journal of Pharmacology and Experimental Therapeutics.

The Anti-Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) D16F7 Monoclonal Antibody Inhibits Melanoma Adhesion to Soluble VEGFR-1 and Tissue Invasion in Response to Placenta Growth Factor

P. Lacal, M. Atzori, M. Scimeca, 2022, Cancers.

Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.

L. Tentori, P. Lacal, M. Atzori, 2020, Pharmacological research.

Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib

M. Barbaccia, L. Tentori, P. Lacal, 2019, Journal of cellular and molecular medicine.

Poly(ADP-ribose) polymerase inhibitor olaparib hampers placental growth factor-driven activation of myelomonocytic cells.

L. Tentori, P. Lacal, M. Atzori, 2018, Oncology reports.

The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells

R. Pallini, R. Bjerkvig, L. Tentori, 2017, Journal of Experimental & Clinical Cancer Research.

Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding

L. Tentori, P. Lacal, G. Graziani, 2016, Oncotarget.

Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer drugs.

L. Tentori, P. Lacal, L. Levati, 2005, International journal of oncology.

Pharmacological inhibition of poly ( ADP-ribose ) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells

L. Tentori, P. Lacal, Jie Zhang, 2022 .

TARGETING OF PDGF-C/NRP-1 AUTOCRINE LOOP AS A NEW STRATEGY FOR COUNTERACTING THE INVASIVENESS OF MELANOMA RESISTANT TO BRAF INHIBITORS.

P. Lacal, L. Levati, S. Caporali, 2023, Pharmacological research.

Neuropilin‐1 is required for endothelial cell adhesion to soluble vascular endothelial growth factor receptor 1

P. Lacal, V. Morea, Patrizio Di Micco, 2021, The FEBS journal.

Platelet-derived growth factor-C promotes human melanoma aggressiveness through activation of neuropilin-1

P. Lacal, L. Levati, S. Caporali, 2017, Oncotarget.

Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-κB.

P. Lacal, L. Levati, K. Umezawa, 2010, International journal of oncology.

Neuropilin-1 expression promotes invasiveness of melanoma cells through vascular endothelial growth factor receptor-2-dependent and -independent mechanisms.

P. Lacal, F. Ruffini, S. D’Atri, 2013, International journal of oncology.

Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide.

C. Leonetti, M. Scarsella, L. Tentori, 2005, European journal of cancer.

Placenta growth factor and neuropilin-1 collaborate in promoting melanoma aggressiveness.

P. Marchetti, P. Lacal, G. Graziani, 2016, International journal of oncology.

Pharmacological inhibition of PDGF-C/neuropilin-1 interaction: A novel strategy to reduce melanoma metastatic potential.

F. Iacovelli, M. Falconi, F. Lozzi, 2024, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Vascular endothelial growth factor receptor 1 in glioblastoma‑associated microglia/macrophages.

P. Lacal, L. Lisi, P. Navarra, 2020, Oncology reports.

The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma.

L. Tentori, P. Lacal, G. Graziani, 2008, Oncology reports.